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NAFLDThe interest in adiponutrin stems from adiponutrin variant I148M, which is strongly associated to non-
alcoholic fatty liver disease. Adiponutrin has to date been considered to be solely an intracellular protein,
with a role in lipid metabolism in liver and adipose tissue. However, a physiologically relevant role for
adiponutrin has not been found. The aim of this study was to investigate the presence of adiponutrin
in human plasma, a new facet of adiponutrin research. We demonstrate that adiponutrin is present in
plasma as disulﬁde-bond dependent multimers, estimated to circulate at a concentration of 1.25–
4 nM. Experiments reveal that adiponutrin is released from HepG2 cells in the presence of oleate. The
presence of adiponutrin in plasma makes it accessible for clinical investigations and use as a potential
biomarker for metabolic disease.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
It is well established that a nonsynonymous polymorphism in
PNPLA3 (rs738409, Adiponutrin (ADPN) I148M), has momentous
impact on the susceptibility of non-alcoholic fatty liver disease
(NAFLD) [1–5]. To date ADPN has been proposed to exhibit triacyl-
glycerol (TG) hydrolase activity [6–9], that is lost in the ADPN-
148M variant [9,10], and lysophosphatidic acid acyltransferaese
activity (LPAAT) [11], in which ADPN-148M is a gain of function
mutation. Recent papers put ADPN into an intracellular context
involving the regulation of lipid ﬂux in hepatocytes [12,13]. The
former reporting that ADPN affects hepatic very low density
lipoprotein (VLDL) secretion in humans and in vitro, hypothesizing
that the loss of lipase activity in ADPN-148M reduces the lipidation
of Apolipoprotein B100 (ApoB100) promoting hepatic lipid
accumulation [12].
Here we present data that widens the prospective physiological
role of ADPN to encompass a systemic function as a circulatory
plasma protein. Recently it came to our attention that The Plasma
Proteome Database (PPD) [14] lists several of the PNPLA proteinfamily members and among them ADPN as a plasma protein based
on two global proteomic analyses of plasma and serum, respec-
tively [15,16]. In these respective studies ADPN appears at the bot-
tom of a long peptide hit list found in the Supplemental material
and are not mentioned in the result section. Consequently, this fa-
cet of ADPN physiology has not been investigated previously. Here
we characterize ADPN in human plasma and show that ADPN is
present in plasma in disulﬁde bond-dependent high molecular
weight complexes, much in analogy with the plasma adiponectin
multimers characterized in 2003 by Waki et al. [17]. ADPN multi-
mers are also present intracellularly in HepG2 and 3T3L1 cells.
Further, ADPN is released from HepG2 cells in the presence of
oleate and co-localizes with the major protein component of VLDL
ApoB100. The presence of ADPN in human plasma makes it
accessible for clinical evaluation, possibly as a biomarker for
liver-related diseases.
2. Materials and methods
2.1. Treatment of samples and immunoblotting
Human plasma was collected from heparinized or EDTA treated
blood from healthy donors (male and female, age 30–60 years,
non-fasted, n = 5). Plasma was cleared from albumin and IgG with
ProteoExtract Albumin/IgG Removal Kit (Calbiochem) and concen-
trated to starting volume using a Savant SpeedVac Concentrator.
SDS–PAGE sample buffer: 3% SDS, 50 mM Tris–HCl pH 6.8, and
10% glycerol, with or without 5% 2-mercaptoethanol and 10 mM
DTT and with or without subsequent heating of the samples to
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prior to separation. Protocol for collection (Dnr 2009/23) and anal-
ysis (supplement Dnr 2012/135) of human plasma was approved
by The Regional Ethical Review Board, Lund, Sweden. The approved
protocol included written informed consent to participate.
Proteins were separated using the NuPAGE Novex Bis-Tris (4–
12%) mini Gel System, Life Technologies (Invitrogen). Native gel
electrophoresis was done using Bis-Tris native gel system (Native-
PAGE Novex Bis-Tris Gel System, Life technologies). Detection of
immunoreactivity was performed using enhanced chemilumines-
cence kit (Pierce, Thermo Scientiﬁc) and the ChemiDoc™
XRS + camera and Image Lab (Bio Rad) software was used for
visualization.
The concentration of plasma ADPN was analyzed using a pep-
tide of human ADPN (residue 196–209 from Innovagen, Sweden)
as standard. The samples and the standard were transferred to a
nitrocellulose membrane using a slot blot device. Recombinant
ADPN-GST was purchased from Abnova, Taiwan. To evaluate the
speciﬁcity of the in-house ADPN antibody (ab4), the antibody
was preabsorbed with 10 lg peptide for 2 h before using it for
detection of ADPN.
2.2. Cells and tissues
HepG2 cells were cultured in DMEM supplemented with 10%
Fetal Calf Serum, 100 U/ml penicillin and 100 lg/ml streptomycin
at 37 C in 95% air/5% CO2. Transfection of HepG2 cells was con-
ducted using polyethylenimine (Polysciences, Eppelheim, Ger-
many) 24 h pre experimentation. Human ADPN, NP079051.2
(I148-wildtype) was tagged with an C-terminal HIS-tag and sub-
cloned into Dual-CCM vector. The wildtype construct was sub-
jected to site directed mutagenesis to generate I148M
(QuickChange Multi Site-Directed Mutagenesis Kit from Strata-
gene, US).
Mouse liver and adipose tissue (C57Bl/6 mice), removed post
mortem, was rinsed in PBS and placed on dry ice. Pieces
(200 mg) were placed in 600 ll ice cold homogenization buffer
(used above). The tissues were cut several times with scissors;
homogenized using a glass/glass homogenizer, centrifuged at
1000g at 4 C, for 10 min and the infranatant was collected. The
protocol for collection of mice tissue was approved by Malmö/Lund
Committee for Animal Experiment Ethics, Lund, Sweden (M202-08
and M185-11).
2.3. Fractionation
HepG2 cells transfected with empty vector, wildtype or I148M
ADPN, (described above), were incubated in with or without oleic
acid (described below), were homogenised using a glass-Teﬂon
homogeniser at 4 C in a buffer containing; 10 mM HEPES, 0.3 M
sucrose and 2 mM DTT, pH 7.0 supplemented with protease inhib-
itors. Fractionation was performed using successive pelletation by
increasing g-force. Proteins were separated on SDS–PAGE and ana-
lysed as described above.
Secretion studies – HepG2 were starved in a glucose free Krebs–
Ringer HEPES (KRH) buffer, pH 7.4, 2 h prior stimulation. The KRH
buffer was changed to KRH with or without 360 lM oleic acid (Sig-
ma) complexed to fat free BSA (Roche) for 2 h. The KRH medium
was collected and used for immunoprecipitation using the ADPN
antibody (ab4) or the ApoB100 antibody and protein A Sepharose.
2.4. Immunoprecipitation
Preparation of IP columns and the IP were performed using
Pierce Co-Immunoprecipitation (Co-IP) Kit (Thermo Scientiﬁc)
according to the instructions by the manufacturer. Columns werecoated with Ab 69170 (Ab1) (10 lg), Ab 81874 (Ab3) (12.5 lg) or
anti-ADPN rabbit (37 lg) (Ab4).
IP using protein A Sepharose; 100 ll of plasma was diluted 5
times in 50 mM Tris–HCl, pH 7.0. For analysis of media from HepG2
cells it was diluted twice. The diluted samples were then pre-
cleared by the addition of 50% protein A Sepharose slurry for 1 h
at RT. ADPN antibody (ab4, 2.5 lg) or ApoB100 antibody was added
to the supernatant together with 50% Protein A Sepharose slurry
and incubated ON at 4 C. The Sepharose beads were washed in
50 mM Tris–HCl pH 7.0 four times. 50 mM Tris–HCl, pH 7.0 and
sample buffer, including reducing agents, was added and heated
at 95 C for 10 min.2.5. Immunocytochemistry
HepG2 cells seeded on coverslips were transfected with ADPN-
GPF using polyethylenimine (Polysciences, Eppelheim, Germany).
Human ADPN, NP079051.2 (I148), was subcloned into expression
vector pQBI 25 (Wako Chemicals USA, Inc.), using restriction sites
HindIII and KpnI. Twenty-four hours post transfection the cells
were ﬁxed in 4% paraformaldehyde/phosphate-buffered saline for
5 min. Primary antibody incubations were done in KRH 1% BSA
supplemented with 0.1% saponin (Sigma) using MTTP antibody,
ApoB100 antibodies or ADPN antibody (ab3). Secondary antibody
(Alexa 568) and GFP were imaged on an LSM510 confocal micro-
scope (Carl Zeiss MicroImaging, Inc., NY) using planapochromat
60 NA 1.45 oil objective. A multitrack protocol with sequential
excitation was utilized to minimize cross-talk between channels.3. Results
3.1. Several members of the PNPLA protein family members are
predicted to be secretory
ADPN has been considered to be solely an intracellular mem-
brane associated protein (as it is described on UniProt), partly be-
cause the amino acid sequence of ADPN does not contain a classical
secretion signal (veriﬁed using sequence NP_079501.2/Q9NST1) in
the SignalP 4.1 [18] server provided by Center of Biological Se-
quence Analysis (CBS) at the Technical University of Denmark
(DTU). However, evidence is emerging of signal-less proteins that
are secreted in a non-classical way, an example being FGF [19]. In-
deed, when ADPN is run through SecretomeP 2.0 [20], provided by
CBS at DTU, it is predicted to be a non-classically secreted protein
(Table 1). The other eight PNPLA protein family members were also
run through SecretomeP 2.0 and ﬁve out of the remaining eight
members attained a NN-score >0.5, which is considered predictive
for secretion in the non-classical pathway (Table 1). Of the three
that were not predicted to be subject to signal-less secretion,
PNPLA4 was predicted to contain a classical secretion signal (aa
1–24) (Table 1), a ﬁnding that has not been reported by other pre-
diction servers such as UniProt. Follow up searches for the listing of
ADPN and the other PNPLA protein family members in the Plasma
Protein Database (PPD) [14] and the Proteomics Identiﬁcations
Database (PRIDE) [21] revealed that ADPN protein peptides, as well
as peptides from other family members, have been detected in the
blood and in media collected from human umbilical vein endothe-
lial cells (HUVEC) [22] (Table 1). Of the listed PNPLA proteins
ADPN, PNPLA6 [Neuropathy target esterase (NTE)] and PNPLA9
[85/88 kDa calcium-independent phospholipase A2 (beta)] are pre-
dicted to be secreted, appear in listings of detected plasma proteins
and are secreted by HUVECs. The data generated by SecretomeP 2.0
or the listed data in PPD and PRIDE concerning ADPN and the other
PNPLA proteins, have to our knowledge not been veriﬁed.
Table 1
Secretion prediction of PNPLA family proteins and investigation into proteomics listings in human plasma and media from HUVEC.
Gene Protein Secretion
prediction
Secretory signal
peptide
Plasma Proteome
Database
PRIDE
Plasma
PRIDE secretion by
HUVEC
Length
(aa)
kDa
PNPLA1 PNPLA1
p
– – –
p
532 57
PNPLA2 Adipose triglyceride Lipase (ATGL)
p
– – – – 504 55
PNPLA3 Adiponutrin (ADPN)
p
–
p p p
481 52
PNPLA4 GS2 –
p p p
– 253 27
PNPLA5 GS2-like protein
p
– –
p
– 429 48
PNPLA6 Neuropathy target esterase (NTE)
p
–
p p p
1366 149
PNPLA7 Neuropathy target esterase related
protein (NRE)
– – –
p p
1317 145
PNPLA8 Calcium-independent phospholipase A2-
gamma
– –
p p p
782 88
PNPLA9 85/88 kDa calcium-independent
phospholipase A2 (beta)
p
–
p p p
806 89
Secretion prediction using SecretomeP 2.0 and secretory signal peptide predicted by SignalP 4.1 Server, CBS, DTU.
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To demonstrate the presence of ADPN in human plasma; sam-
ples were depleted of albumin and IgG and subjected to SDS–PAGE
with subsequent immunodetection using four different ADPN anti-
bodies (ab1–4, amino acid sequences used as immunogens are
illustrated in Fig. 1A). The immunoblots demonstrate the presence
of ADPN in human plasma at the predicted molecular weight of
52 kDa using all four antibodies (ab1–4) (Fig. 1B), although addi-
tional bands are also visible. The appearance of additional bands
may reﬂect cross-reactivity with other PNPLA protein family mem-
bers. However, aside from Ab1 which is produced against full-
length ADPN, the immunogen sequences have been selected to
minimize cross reactivity between PNPLA family members and
ADPN. Ab4 is an in house peptide antibody raised against aa
196–209 selected to minimize cross reactivity between PNPLA pro-
tein family members and to maximize reactivity to ADPN of human
and rodent origin. Ab4 shows the least number of unspeciﬁc bands
and detects a strong 52 and >100 kDa band (a putative dimer).
To estimate the concentration of ADPN in human plasma a stan-
dard curve was created using the peptide used to produce ADPN
antibody ab4 (Fig. 1A). The standard curve, ranging from 1 toFig. 1. ADPN is present in human plasma. (A) Schematic representation of the primary st
(B) Human plasma cleared from IgG and albumin separated on SDS–PAGE with subs
membrane immunostained with anti-ADPN ab4. ADPN peptide 196–209 and 5 or 2.5 ll o
membrane. (D) Bands from Fig. 1C were detected using a ChemiDoc™ with LabImage Soft
ADPN concentration. (E) Recombinant ADPN-GST (75 kDa) and cleared plasma samples w100 ng ADPN peptide, and albumin/IgG depleted plasma samples
were spotted onto a nitrocellulose membrane using a slot blot de-
vice and subsequently immunoblotted with ADPN ab4 (Fig. 1C).
Bands were detected using a ChemiDoc™ with LabImage Software
from BIO-RAD and the volume intensity was calculated (Fig. 1D).
From the slot blot (Fig. 1C) and the standard curve (Fig. 1D) the
plasma concentration of ADPN is estimated to 0.8 ± 0.01 ng/ll
plasma, corresponding to 15.4 nM. The plasma concentration of
ADPNwas also estimated using relative quantitation of band inten-
sities comparing recombinant ADPN-GST and plasma ADPN run on
a SDS–PAGE and subsequent immunoblotting (Fig. 1E), yielding a
concentration of 2.5 ± 0.5 ng/ll plasma, corresponding to a plasma
concentration of 48 nM. Collectively, these data indicate that the
plasma concentration of ADPN is in the approximate range of
0.8–2.5 lg/ml or 15–48 nM.
3.3. Plasma ADPN exists as high molecular weight multimers
To follow up on the putative ADPN dimers detected under
reducing and denaturing conditions (Fig. 1B), plasma samples were
prepared and separated on a Native PAGE gel. Immunodetection of
ADPN revealed two large complexes of approximate molecularructure of ADPN with indicated regions used to produce 4 different ADPN antibodies
equent immunoblotting with four different ADPN antibodies (n = 4). (C) Slot Blot
f albumin and IgG depleted human plasma was spotted directly onto a nitrocellulose
ware from BIORAD and the volume intensity was calculated and graphed against the
ere separated on SDS–PAGE and subsequently immunoblotted using anti-APDN ab4.
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(Fig. 2A), indicating that ADPN does not natively occur in a mono-
meric (52 kDa) or dimeric (100 kDa) form. Intracellular ADPN, ex-
pressed in liver and adipose tissue (mouse) or the cell lines; (i)
human hepatoma HepG2 and (ii) 3T3-L1 adipocytes, was also so-
lely found to be present in large molecular complexes ranging from
250 to 700 kDa (Fig. 2A, right). To test if the high molecular weight
ADPN complexes were an artifact of sample preparation under na-
tive conditions, such as protein–protein interaction due to hydro-
phobic forces or membrane association, HepG2 cell homogenates
and plasma samples were treated with n-dodecyl-b-D-maltoside
(DDM) or Digitonin, two detergents used to solubilize proteins
from membranes or preventing them from forming complexes.
Treatment with DDM or Digitonin did not affect the integrity of
ADPN high molecular weight complexes in HepG2 cells (Fig. 2A,
center) or in plasma (Fig. 2B). To further verify the existence of
ADPN multimers in human plasma, immunoprecipitation experi-
ments were performed using two different ADPN antibodies
(Fig. 2C). The results show that immunoprecipitates contain tri-
mers or larger complexes of ADPN, under non-reducing non-dena-
turing conditions.3.4. Plasma ADPN multimers are disulﬁde bond-dependent
To elucidate if ADPN multimers are disulﬁde bond-dependent,
albumin and IgG depleted human plasma was prepared for SDS–
PAGE under non-reducing non-denaturing conditions, denaturing
conditions, reducing conditions or a combination of reducing and
denaturing conditions. Analysis revealed that ADPN exists in com-
plexes >250 kDa under non-reducing non-denaturing conditionsFig. 2. ADPN exists in high molecular weight multimers in plasma and tissues. (A) Human
from left to right: lanes 1–2, human plasma, lane 3, (human) HepG2 liver cell line, lan
adipocyte homogenate. Immunoblotted using ab3 (n = 3). HepG2 cell homogenates in the
Digitonin (Dig) prior to gel separation. (B) Human plasma run on a Native PAGE gel treat
using anti-ADPN antibodies ab1 and ab2, in an IP column. Samples were run on SDS–PAGE
Cleared human plasma run on SDS–PAGE and immunoblotted against ADPN ab4. Lane 1,
lane 4, denatured and reduced (n = 4).on an SDS–PAGE and that the complexes are reduced in size by
reduction of disulﬁde bonds, yielding dimers (100 kDa)
(Fig. 2D). ADPN is found almost exclusively as a monomer under
reducing and denaturing conditions (Fig. 2D). To rule out the pos-
sibility of unspeciﬁc bands an identical blot, as in Fig. 2A, was sub-
jected to preabsorbed anti-APDN antibody and developed in the
same manner (Supplemental Fig. 1A). The preabsorption experi-
ment revealed that the 70 kDa band probably is unspeciﬁc while
detection of all other bands from Fig. 2D was blocked. Further,
sample preparation to test the multimeric nature of ADPN de-
scribed above, revealed that also puriﬁed recombinant ADPN-GST
exist in disulﬁde-bond dependent multimers >250 kDa on an
SDS–PAGE and that these multimers monomerize under reducing
conditions (Supplemental Fig. 1B).3.5. ADPN secretion
To explore the hepatocyte as a site of ADPN release and possible
co-release with VLDL, HepG2 cells were incubated with BSA-com-
plexed oleate (360 lM) for 2 h. Analysis of the collected media
show the presence of ADPN and ApoB100 (Fig. 3A), respectively.
As expected the ApoB100 protein level increases in the medium
in the presence of oleate but there was no difference in ADPN
levels in the medium between the treatments. A possible direct
interaction between ADPN and ApoB100 was investigated in
co-immunoprecipitation experiments from HepG2 homogenates
and human plasma. The results show that ApoB100 and ADPN
co-immunoprecipitate from the homogenate (Fig. 3B) and a small
amount of the total ApoB100 is associated to ADPN in plasma
(Fig. 3C), suggesting co-secretion. Accordingly, the inferredplasma, mouse adipocyte and liver homogenates run on a Native PAGE gel. In order
e 4, mouse liver homogenate, lane 5, 3T3-L1 adipocyte cell line and lane 6, mouse
central panel were treated with or without 1.5% n-dodecyl-b-D-maltoside (DDM) or
ed DDM or Dig prior to gel separation. (C) hADPN immunoprecipitated from plasma
under non-denaturing and non-reducing conditions, ADPN antibody ab3 (n = 2). (D)
non-denatured and non-reduced, lane 2, denatured by heating, lane 3, reduced and
Fig. 3. ADPN is secreted by HepG2 cells and co-localizes with VLDL. (A) HepG2 cells were starved in KRH buffer for 2 h and the medium was switched to a KRH buffer with or
without 360 lM oleate for 2 h. The medium was used for immunoprecipitation using protein A Sepharose (ADPN ab4) and immunodetection of ApoB100 and ADPN ab3,
respectively (n = 2). (B) Immunoprecipitated ApoB100, using protein A Sepharose, from HepG2 homogenates was run on a SDS–PAGE gel and immunoblotted for ADPN ab 3
(n = 2). Unbound (UnB). (C) ADPN immunoprecipitated ab4, using a column, from 100 ll and 50 ll human plasma, P1 and P2 (n = 2), respectively, run on SDS–PAGE and
immunoblotted against ApoB100 and ADPN ab2, respectively (n = 3). (D) HepG2 cells transfected with recombinant ADPN-GFP. Twenty-four hours post transfection the cells
were ﬁxed and stained with ApoB100, MTTP or ADPN antibodies (as indicated in the ﬁgure). Scale bar = 10 lm, (n = 2).
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gated by expression of recombinant ADPN-GFP in HepG2 cells
co-stained with antibodies directed towards ApoB100 and micro-
somal triglyceride transfer protein (MTTP), a protein involved in
lipidation of ApoB100, and ADPN. Confocal imaging revealed that
ADPN-GFP co-localizes with both ApoB100 and MTTP in HepG2
cells (Fig. 2D). The intracellular localization of recombinant
ADPN-GFP was veriﬁed by co-staining of endogenous ADPN (Fig-
ure D, bottom row).4. Discussion
This report presents the ﬁrst characterization of plasma ADPN.
Plasma ADPN has to date not been described although ADPN has
previously been reported in plasma and serum in two independent
global proteomics reports published in The Plasma Proteome Data-
base [15,16]. In these respective studies no biochemical or molec-
ular data was presented with regard to ADPN. The reports present
two to three ADPN peptides listed in the Supplemental material.
Further, the PRIDE database which is a repository of reported glo-
bal proteomics experiments from different tissues reports the pres-
ence of ADPN in several plasma experiments but also in collected
media from HUVECs. Interestingly, data mining into the behavior
of the other eight PNPLA protein family members revealed that
many of them can be detected in plasma and as secretory from HU-
VECs, hence unraveling a new characteristic of this protein family.
The secretory nature of the PNPLA protein family has gone unno-
ticed partly because of the lack of predicted classical secretion sig-
nals. The SignalP 4.1 Server [18] provided by CBU used to predict
classical secretion signals is continuously being reﬁned and im-
proved leading to better predictions. An unexpected ﬁnding pre-
sented in this report is that PNPLA4 (GS2) is predicted to exhibit
a classical secretion signal within the ﬁrst 24 N-terminal amino
acids. The other eight family members do not contain a classicalsignal for secretion but six of these are predicted to be secreted
in the non-classical way using SecretomeP 4.1. The appearance of
ADPN, PNPLA4, PNPLA6 and PNPLA9 in plasma (several different
studies) and/or HUVEC media in combination with either the pre-
diction of non-classical secretion or the presence of a secretion sig-
nal (PNPLA4) collectively supports an extracellular role for this
group of proteins that has not been explored.
In this report we estimate the plasma concentration of ADPN to
lie in the range of 0.8–2.5 lg/ml or 15–48 nM, not taking into ac-
count that ADPN exists as multimers in plasma. If the multimeric
nature of ADPN is concidered the concentration is 12 times less
i.e., 1.25–4 nM (0.8–2.5 lg/ml). To place this concentration into
context of metabolically active circulating plasma proteins; (i)
insulin circulates in plasma at a concentration ranging from low
pM to 600 pM, depending on the current glucose concentration
[23] and (ii) adiponectin, a multimeric plasma protein secreted
from adipocytes, is found to circulate at 5–10 lg/ml, constituting
0.01% of the total plasma protein content [24]. Hence, the concen-
tration of plasma ADPN of 1.25–4 nM (0.8–2.5 lg/ml) is quite
substantial and is consequently easily detectable in plasma using
immunobased methods.
The ﬁnding of a novel plasma protein raises questions about its
site of secretion. Here we show that ADPN is secreted from HepG2
cells under basal conditions and in presence of oleate. Previously
APDN has been considered to be solely an intracellular membrane
associated protein (as it is described on UniProt), partly because
the amino acid sequence of ADPN does not contain a classical
secretion signal. In view of the results in this report, showing that
ADPN co-localizes with ApoB100 in HepG2 cells and is partially
associated to ApoB100 in plasma, it is possible that ADPN is co-se-
creted with ApoB100-containing lipoprotein particles mediating its
exit route in this way, a ﬁnding that needs to be validated in in vivo
experiments in humans.
In the perspective of published reports associating ADPN to
obesity and liver steatosis, it is of interest to study ADPN in the
M.E. Winberg et al. / Biochemical and Biophysical Research Communications 446 (2014) 1114–1119 1119circulation and to ﬁnd a potential target tissue and/or receptor.
Measurements of plasma ADPN have the potential to become a
clinical marker for liver status and other metabolic traits.
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